SCHEMBL14520037

SCHEMBL14520037

COc1ccc(C)cc1S(=O)(=O)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.57
▸ USP2 O75604 1/20 0.57
▸ GAA P10253 1/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ TSHR P16473 2/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ RECQL P46063 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ MAPK1 P28482 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ CASP1 P29466 1/20 0.49
▸ ACHE P22303 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12180447 0.86 MCOLN3 (0.53) KMT2AUSP2GAASMN1; SMN2MEN1
SCHEMBL14519874 0.82 L3MBTL1 (0.60) KMT2AGAASMN1; SMN2L3MBTL1LMNA
SCHEMBL14519923 0.81 ALDH1A1 (0.55) KMT2AUSP2GAASMN1; SMN2MEN1
SCHEMBL14519921 0.81 SMN1; SMN2 (0.56) KMT2AGAASMN1; SMN2MEN1TSHR
SCHEMBL14520042 0.81 MAOB (0.44) KMT2AUSP2GAASMN1; SMN2TSHR
SCHEMBL12180426 0.79 SMN1; SMN2 (0.67) KMT2AUSP2GAASMN1; SMN2MEN1
SCHEMBL10959144 0.79 ALDH1A1 (0.54) KMT2AGAASMN1; SMN2MEN1L3MBTL1
SCHEMBL12962526 0.78 NPSR1 (0.67) KMT2ASMN1; SMN2MEN1TSHRL3MBTL1
SCHEMBL13290942 0.78 KMT2A (0.60) KMT2AUSP2GAASMN1; SMN2MEN1
SCHEMBL739940 0.78 KMT2A (0.60) KMT2AUSP2GAASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 KMT2A 1449/4885USP2 1344/4885GAA 4203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback